Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Glipizide (compound)

Name: Glipizide
PubChem Compound ID: 34470
Description: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
Molecular formula: C22H28N4O4S
Molecular weight: 444.548 g/mol
Glipizide; 29094-66-4
Name: Glipizide
Name (isomeric): DB01067
Drug Type: small molecule
Description: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
Glipizida [INN-Spanish]; Glydiazinamide; Glipizidum [INN-Latin]
Brand: Glipizide Extended-Release Tablets, Aldiab, Glucolip, Minodiab, Melizide, Gluco-Rite, Mindiab, Glucotrol, Glyde, Dipazide, Glucotrol XL, Sucrazide, Glibetin, Napizide, Digrin, Glucozide, Glupitel, Ozidia, Metaglip, Glibenese, Glupizide, Glidiab, Glipid, Glide, Minidab, Minidiab, Glican
Category: Hypoglycemic Agents
CAS number: 29094-61-9
Indication: For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.
Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pan...
show more »
Mechanism of Action:
Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, ...
show more »
Absorption: Gastrointestinal absorption is uniform, rapid, and essentially complete.
Protein binding: 98-99%, primarily to albumin.
Biotransformation: Hepatic. The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylaminoethyl benzine derivatives, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound.
Route of elimination: The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine.
Half Life: 2-5 hours
Toxicity: The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia.
Affected organisms: Humans and other mammals
Food interaction:
Avoid alcohol.
Take 30-60 minutes before breakfast.
Avoid sugar and sugary food.
Drug interaction:
PindololThe beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
TolbutamideTolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
PhenylbutazonePhenylbutazone increases the effect of the hypoglycemic agent
OxprenololThe beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
RifampinRifampin may decrease the effect of sulfonylurea, glipizide.
show more »